Key result
Atherosclerosis linked to accelerated PGI2 degradation, blunting antiaggregation drug effects.
Why the study?
Patients with atherosclerosis have enhanced velocity of prostacyclin degradation, which may influence the antiaggregation effects of certain drugs.
Does the velocity of prostacyclin degradation correlate with the antiplatelet effects of pentoxifylline, nifedipine, and dipyridamole in patients with atherosclerosis?
Observational (n=179)
Does the velocity of prostacyclin degradation correlate with the antiplatelet effects of pentoxifylline, nifedipine, and dipyridamole in patients with atherosclerosis?
The antiplatelet efficacy of drugs like pentoxifylline, nifedipine, and dipyridamole may be attenuated in patients with atherosclerosis due to accelerated degradation of prostacyclin.
Enhanced PGI2 degradation may attenuate antiaggregatory effects of pentoxifylline, nifedipine, and dipyridamole in atherosclerosis; extends mechanisms of variable platelet inhibition.
Blood and plasma from 109 patients with atherosclerosis and 70 healthy volunteers were tested to study the rate of prostacyclin (PGI2) hydrolysis. It has been reported that patients with atherosclerosis have the enhanced velocity of PGI2 degradation. The increase in the velocity was more marked in blood than in plasma. The significant negative correlation between antiaggregation effects of pentoxifylline, nifedipine, and dipyridamole and the velocity of PGI2 degradation in the patients was found. These data suggest that the increase of PGI2 biosynthesis by the drugs studied can enhance their antiaggregation effect if processes of PGI2 degradation in blood are not accelerated.
No takes yet. Share an insight, caveat, or question.
Akopov et al. (1993) conducted an observational in Atherosclerosis (n=179). Atherosclerosis vs. Healthy volunteers was evaluated on Velocity of PGI2 degradation and correlation with antiaggregation drug effects. Atherosclerosis was associated with enhanced PGI2 degradation velocity, which negatively correlated with the antiaggregation effects of pentoxifylline, nifedipine, and dipyridamole.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: